Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata
Sponsor: Jiangsu vcare pharmaceutical technology co., LTD
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy and safety of VC005 tablets in subjects with severe alopecia areata (AA).
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Severe Alopecia Areata
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2026-08-18
Completion Date
2028-12-30
Last Updated
2026-08-27
Healthy Volunteers
No
Conditions
Interventions
Drug: VC005 tablets
VC005 repeat administration for 24 weeks
VC005 tablets
VC005 repeat administration for 24 weeks
VC005 placebo tablets
VC005 placebo repeat administration for 24 weeks
Locations (1)
The Peking University People's Hospital, Beijing, Beijng
Beijing, Beijing Municipality, China